89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB) has announced the approval of inducement grants for seven new employees by its Board's Compensation Committee. The grants consist of non-qualified stock options to purchase 183,885 shares of common stock, issued on May 6, 2025. These grants, made under the company's 2023 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4) and serve as employment incentives. The options' exercise price equals ETNB's closing price on the grant date and will vest over four years - 25% after one year and the remaining in 12 quarterly installments, contingent on continued employment.
89bio (Nasdaq: ETNB) ha annunciato l'approvazione di concessioni incentivanti per sette nuovi dipendenti da parte del Comitato per la Retribuzione del Consiglio di Amministrazione. Le concessioni consistono in opzioni su azioni non qualificate per l'acquisto di 183.885 azioni ordinarie, emesse il 6 maggio 2025. Queste concessioni, effettuate nell'ambito del Piano Incentivante 2023 della società, seguono la Regola Nasdaq 5635(c)(4) e rappresentano incentivi all'assunzione. Il prezzo di esercizio delle opzioni corrisponde al prezzo di chiusura di ETNB alla data di concessione e matureranno nell'arco di quattro anni - il 25% dopo un anno e il restante in 12 rate trimestrali, subordinatamente alla permanenza in servizio.
89bio (Nasdaq: ETNB) ha anunciado la aprobación de subvenciones de inducción para siete nuevos empleados por parte del Comité de Compensación de su Junta Directiva. Las subvenciones consisten en opciones sobre acciones no calificadas para comprar 183,885 acciones ordinarias, emitidas el 6 de mayo de 2025. Estas subvenciones, realizadas bajo el Plan de Inducción 2023 de la compañía, cumplen con la Regla 5635(c)(4) de Nasdaq y sirven como incentivos laborales. El precio de ejercicio de las opciones es igual al precio de cierre de ETNB en la fecha de la concesión y se consolidarán durante cuatro años - 25% después de un año y el resto en 12 cuotas trimestrales, condicionado a la continuidad en el empleo.
89bio (나스닥: ETNB)는 이사회 보상위원회가 7명의 신입 직원에 대한 유인 보조금 승인을 발표했습니다. 이 보조금은 2025년 5월 6일에 발행된 183,885주의 보통주를 매수할 수 있는 비공인 스톡옵션으로 구성되어 있습니다. 이 보조금은 회사의 2023년 유인 계획에 따라 나스닥 상장 규칙 5635(c)(4)를 준수하며 고용 인센티브로 제공됩니다. 옵션의 행사 가격은 부여일 ETNB 종가와 동일하며, 4년에 걸쳐 베스팅됩니다 - 1년 후 25%, 나머지는 12분기별 할부로 계속 근무 조건에 따라 지급됩니다.
89bio (Nasdaq : ETNB) a annoncé l'approbation de attributions incitatives pour sept nouveaux employés par le comité de rémunération de son conseil d'administration. Ces attributions consistent en des options d'achat d'actions non qualifiées portant sur 183 885 actions ordinaires, émises le 6 mai 2025. Ces attributions, réalisées dans le cadre du Plan d'Induction 2023 de la société, respectent la règle Nasdaq 5635(c)(4) et servent d'incitations à l'emploi. Le prix d'exercice des options correspond au cours de clôture d'ETNB à la date d'attribution et sera acquis sur une période de quatre ans - 25 % après un an et le reste en 12 versements trimestriels, sous réserve de la poursuite de l'emploi.
89bio (Nasdaq: ETNB) hat die Genehmigung von Anreizzuschüssen für sieben neue Mitarbeiter durch den Vergütungsausschuss seines Vorstands bekannt gegeben. Die Zuschüsse bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 183.885 Stammaktien, ausgegeben am 6. Mai 2025. Diese Zuschüsse, die im Rahmen des Inducement-Plans 2023 des Unternehmens gewährt werden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und dienen als Beschäftigungsanreize. Der Ausübungspreis der Optionen entspricht dem Schlusskurs von ETNB am Tag der Gewährung und wird über vier Jahre gestaffelt - 25 % nach einem Jahr und der Rest in 12 vierteljährlichen Raten, vorbehaltlich der fortgesetzten Beschäftigung.
- None.
- None.
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company’s common stock to seven new employees (the “Inducement Grants”) on May 6, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What is the size of ETNB's inducement grants announced on May 9, 2025?
What is the vesting schedule for ETNB's May 2025 inducement grants?
How were ETNB's inducement grants priced in May 2025?
What is the purpose of ETNB's inducement grants announced in May 2025?
